Cargando…

Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial

AIMS: Thiazolidinediones are insulin sensitizers, and are associated with fluid retention and increased risk of heart failure (HF) in people with type 2 diabetes. We assessed fatal and non-fatal HF events and their outcome, and identified HF predictors in the RECORD (Rosiglitazone Evaluated for Card...

Descripción completa

Detalles Bibliográficos
Autores principales:	Komajda, Michel, McMurray, John J.V., Beck-Nielsen, Henning, Gomis, Ramon, Hanefeld, Markolf, Pocock, Stuart J., Curtis, Paula S., Jones, Nigel P., Home, Philip D.
Formato:	Texto
Lenguaje:	English
Publicado:	Oxford University Press 2010
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2848325/ https://www.ncbi.nlm.nih.gov/pubmed/20118174 http://dx.doi.org/10.1093/eurheartj/ehp604

Ejemplares similares

Incidence and Prevalence of Unrecognized Myocardial Infarction in People With Diabetes: A substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study
por: MacDonald, Michael R., et al.
Publicado: (2011)

Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study)
por: Komajda, Michel, et al.
Publicado: (2008)

Rosiglitazone RECORD study: glucose control outcomes at 18 months
por: Home, P D, et al.
Publicado: (2007)

Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials
por: Home, P. D., et al.
Publicado: (2010)

Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes
por: Hanefeld, Markolf
Publicado: (2007)

Rosiglitazone use and associated adverse event rates in Canada between 2004 and 2010
por: Rawson, Nigel SB, et al.
Publicado: (2013)

Insulin Use Early in the Course of Type 2 Diabetes Mellitus: The ORIGIN Trial
por: Hanefeld, Markolf, et al.
Publicado: (2013)

The Current and Potential Therapeutic Use of Metformin—The Good Old Drug
por: Drzewoski, Józef, et al.
Publicado: (2021)

Is Hyperglycemia a Cardiovascular Risk Factor?
por: Pistrosch, Frank, et al.
Publicado: (2011)

Cardiac implications of hypoglycaemia in patients with diabetes – a systematic review
por: Hanefeld, Markolf, et al.
Publicado: (2013)

Leukemia and rosiglitazone
por: Yavasoglu, Irfan, et al.
Publicado: (2016)

Shifting the Disease Management Paradigm From Glucose: What are the cons?
por: Hanefeld, Markolf, et al.
Publicado: (2009)

A review of glucagon‐like peptide‐1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus
por: Owens, David R., et al.
Publicado: (2017)

Rosiglitazone use and associated adverse event rates in Canada: an updated analysis
por: Iczkovitz, Sandra, et al.
Publicado: (2015)

The Janus face of rosiglitazone
por: Pich, Christine, et al.
Publicado: (2018)

Remission of type 2 diabetes and pleiotropic effects of long-term testosterone treatment for “late-onset” hypogonadism: A case report
por: Haider, Ahmad, et al.
Publicado: (2019)

The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL
por: Hanefeld, Markolf, et al.
Publicado: (2017)

Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials
por: Hanefeld, Markolf, et al.
Publicado: (2016)

Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update
por: Hanefeld, Markolf, et al.
Publicado: (2020)

A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people with Type 2 diabetes1
por: Home, P D, et al.
Publicado: (2007)

Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: the Diabetes in Germany (DIG) study
por: Hanefeld, Markolf, et al.
Publicado: (2007)

Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of Pioglitazone, Metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study
por: Hanefeld, Markolf, et al.
Publicado: (2011)

The metabolic vascular syndrome - guide to an individualized treatment
por: Hanefeld, Markolf, et al.
Publicado: (2016)

Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study
por: Juurlink, David N, et al.
Publicado: (2009)

Rapid evidence‐based sequencing of foundational drugs for heart failure and a reduced ejection fraction
por: Packer, Milton, et al.
Publicado: (2021)

Rosiglitazone and Fenofibrate Additive Effects on Lipids
por: Slim, Ahmad, et al.
Publicado: (2011)

SOLOIST‐WHF and updated meta‐analysis: sodium–glucose co‐transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure
por: Docherty, Kieran F., et al.
Publicado: (2020)

PLA-PEG Nanoparticles Improve the Anti-Inflammatory Effect of Rosiglitazone on Macrophages by Enhancing Drug Uptake Compared to Free Rosiglitazone
por: Giacalone, Giovanna, et al.
Publicado: (2018)

Sudomotor Testing of Diabetes Polyneuropathy
por: Krieger, Sarah-Maria, et al.
Publicado: (2018)

Drug therapy for heart failure with reduced ejection fraction: what is the ‘right’ dose?
por: Kondo, Toru, et al.
Publicado: (2022)

Restoring adiponectin via rosiglitazone ameliorates tissue wasting in mice with lung cancer
por: Langer, Henning Tim, et al.
Publicado: (2023)

Incidence of Diabetes Following Ramipril or Rosiglitazone Withdrawal
Publicado: (2011)

Safety and efficacy of rosiglitazone in the elderly diabetic patient
por: Viljoen, Adie, et al.
Publicado: (2009)

Topical Rosiglitazone Is an Effective Anti-Scarring Agent in the Cornea
por: Huxlin, Krystel R., et al.
Publicado: (2013)

Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial
por: Packer, Milton, et al.
Publicado: (2021)

Estimating the Lifetime Benefits of Treatments for Heart Failure
por: Ferreira, João Pedro, et al.
Publicado: (2020)

Statistical methodology for recurrent events, with application to major trials in heart failure
por: Rogers, Jennifer, et al.
Publicado: (2013)

Rosiglitazone and Pioglitazone Utilization from January 2007 Through May 2008 Associated With Five Risk-Warning Events
por: Starner, Catherine I., et al.
Publicado: (2008)

‘Hearts and minds’: association, causation and implication of cognitive impairment in heart failure
por: Cannon, Jane A, et al.
Publicado: (2015)

Talking to patients with heart failure about end of life
por: Campbell, Ross T., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1kmpin97nmcoi06793csd28a7j